Clinical Trial 50058

Rutland, VT 05701


A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks. The safety of simufilam, and its efficacy in enhancing cognition and slowing cognitive and functional decline will be evaluated.

  1. 50 Years to 87 Years
  2. Meets National Institute on Aging and Alzheimer's Association Research Framework criteria for individuals in clinical Stage 4 or 5 of the Alzheimer's continuum.
  3. Evidence for AD pathophysiology, confirmed either prior to or during screening.
  4. MMSE score ≥ 16 and ≤ 27 at screening.
  5. Clinical Dementia Rating - Global Score must be 0.5, 1 or 2.
  6. If receiving background AD medications, the dosing regimen must be stable for at least 12 weeks prior to randomization.
  7. The subject has been a non-smoker for at least 3 years.
  8. Availability of a study partner
  9. Individuals who have participated in a clinical study with an investigational drug targeting the underlying AD process may be permitted to participate in this study.

Qualified Participants May Receive:

• No-cost study medication

• No-cost study-related care from a local doctor

• Compensation 

Available At:

Green Mountain Research Institute
198 North Main Street
Suite C-5
Rutland, VT 05701
View Clinic Location


If you or someone you care for is interested in participating and lives within 50 miles of the location shown, please complete the form below and click 'Submit'

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.